Related Experiment Videos
[Method of biphasic defibrillation in modern electropulse therapy]
Insights
Biphasic defibrillation effectively treats life-threatening cardiac arrhythmias using lower energy, reducing myocardial dysfunction. This advanced electropulse therapy offers improved urgent care for severe heart conditions.
Area of Science:
- Cardiology and Electrophysiology
- Medical Device Technology
Context:
- Cardiovascular diseases, particularly coronary disease, are a leading cause of mortality in developed nations.
- Electropulse therapy, or defibrillation, is critical for managing life-threatening arrhythmias and cardiac arrest.
Purpose:
- To highlight advancements in defibrillation technology, specifically biphasic pulse generation.
- To evaluate the efficacy and benefits of new biphasic pulse technologies in urgent cardiac care.
Summary:
- Biphasic pulses can arrest cardiac arrhythmias with lower current strength compared to monopolar pulses.
- The reduced discharge energy of biphasic pulses significantly decreases postresuscitation myocardial dysfunction.
- Schiller AG's Multipulse Biowave device represents a new development in biphasic pulse technology for severe arrhythmias.
Impact:
- Improved outcomes for patients experiencing severe cardiac arrhythmias.
- Enhanced capabilities in emergency cardiac care and resuscitation protocols.
- Potential reduction in cardiac damage following defibrillation events.
Abstract:
Cardiovascular diseases, primarily coronary disease, remain the leading cause of mortality in the majority of countries with well-developed economy. Electropulse therapy (defibrillation) is the main method helpful in life-threatening arrhythmias leading to heart arrest. The development of devices generating biphasic pulses is in progress now. Clinical trials confirmed the capacity of a bipolar pulse to arrest cardiac arrhythmia with current of lower strength in comparison with monopolar pulses. Due to low discharge energy, the degree of postresuscitation myocardial dysfunction is essentially decreased. New technology of biphasic pulses developed by Schiller AG Firm (Switzerland), based on the use of Multipulse Biowave device, is a new step in development of urgent care potentialities in severe cardiac arrhythmias in risk groups.